119 related articles for article (PubMed ID: 9460336)
1. Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel.
Hainsworth JD
Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):4-9. PubMed ID: 9460336
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.
Hainsworth JD; Jones SE; Mennel RG; Blum JL; Greco FA
J Clin Oncol; 1996 May; 14(5):1611-6. PubMed ID: 8622079
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
5. The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer.
Hainsworth JD
Ann Oncol; 1993; 4 Suppl 2():37-40. PubMed ID: 7688982
[TBL] [Abstract][Full Text] [Related]
6. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
7. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Smith IE; Powles TJ
Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone, L-leucovorin and 5-fluorouracil: an effective and well tolerated first-line treatment for advanced breast cancer.
Lorusso V; Mancarella S; Catino A; Brandi M; Paradiso A; Latorre A; Mastria A; De Mitrio A; Guida M; De Lena M
Tumori; 1999; 85(1):60-4. PubMed ID: 10228500
[TBL] [Abstract][Full Text] [Related]
9. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.
Harper-Wynne C; English J; Meyer L; Bower M; Archer C; Sinnett HD; Lowdell C; Coombes RC
Br J Cancer; 1999 Sep; 81(2):316-22. PubMed ID: 10496359
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer.
Pronzato P; Amoroso D; Ardizzoni A; Bertelli G; Canobbio L; Conte PF; Cusimano MP; Fusco V; Gulisano M; Lionetto R
Am J Clin Oncol; 1987 Oct; 10(5):404-6. PubMed ID: 3310605
[TBL] [Abstract][Full Text] [Related]
13. Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Yen CC; Tung SL; Hsieh RK; Chiou TJ; Liu JH; Wang WS; Chen PM
Jpn J Clin Oncol; 1997 Oct; 27(5):316-20. PubMed ID: 9390208
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
16. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
[TBL] [Abstract][Full Text] [Related]
17. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.
Venturino A; Comandini D; Simoni C; Merlini L; Naso C; Palumbo R; Fusco V; Porcile G; Pronzato P; Rosso R; Repetto L
Breast Cancer Res Treat; 2000 Apr; 60(3):195-200. PubMed ID: 10930106
[TBL] [Abstract][Full Text] [Related]
18. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.
Ron IG; Wigler N; Borovik R; Brufman G; Rizel S; Shani A; Brenner J; Farbstein H; Dale A; Inbar MJ; Brenner HJ; Chaitchik S; Catane R
Am J Clin Oncol; 2001 Aug; 24(4):323-7. PubMed ID: 11474254
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
[TBL] [Abstract][Full Text] [Related]
20. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.
Ron IG; Wigler N; Borovik R; Peretz T; Rizel S; Shani A; Brenner J; Farbstein H; Brenner HJ; Chaitchik S; Catane R; Inbar MJ
Am J Clin Oncol; 2002 Oct; 25(5):520-2. PubMed ID: 12393997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]